- Home
- DTIL vs RAND Comparison
DTIL vs RAND Comparison
Compare DTIL & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | RAND |
|---|---|---|
| Founded | 2006 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 32.4M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DTIL | RAND |
|---|---|---|
| Price | $5.62 | $11.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 180.7K | 4.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.29% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $10.05 |
| 52 Week High | $8.82 | $22.13 |
Technical Indicators
Market Signals| Indicator | DTIL | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 54.80 |
| Support Level | $4.50 | $10.31 |
| Resistance Level | $5.80 | $12.50 |
| Average True Range (ATR) | 0.36 | 0.50 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 79.86 | 78.29 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.